NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 37-17817-01

Docket or Reference number: 030-13374

Amendment No. 08

"OFFICIAL RECORD COPY"

J. F. Kennedy Memorial Hospital
Cheltenham and Langdon Streets
Philadelphia, Pennsylvania 19124

In accordance with letter dated March 27, 1985, License Number 37-17817-01 is amended as follows:

Items 6., 7., 8. and 9. are amend to read:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 6.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Iodine 131	C. Any iodide that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	C. 100 millicuries
D. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	D. Prepackaged kits	D. 3 millicuries of each byproduct material authorized in Subitem 6.D.

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. For treatment of hyperthyroidism, cardiac dysfunction, or thyroid carcinoma.
D. In vitro studies.

8512100319 851105
REG1 LIC30
37-17817-01 PDR

ML10

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 37-17817-01
Docket or Reference number 030-13374
Amendment No. 08

(Continued) CONDITIONS

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

James R. Williams, M.D.	In vitro studies
Rajkumari B. Balchandani, M.D.	Groups I, II, and III In vitro studies Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma
Max M. Cooper, M.D.	Groups I, II and III except generators Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma Iodine 131 as Iodinated Human Serum Albumin for blood and plasma volume determinations

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated April 19, 1983 including ALARA Program and letters dated March 27, 1985, June 19, 1985, September 24, 1985, September 26, 1985 and letter received October 22, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date NOV 0 5 1985

By Original Signed By:
Jenny M. Johnson
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406